Clinical trials: Lung Volume
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Emphysema
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.
- Trial name
- LIBERATE (NCT01796392)
- Testing
- EBV, Optimal Medical Management
- Where
- 23 sites in United States, Brazil and 2 more
- Volunteers
- 190 people
- Sponsor
- Pulmonx Corporation
Prolonged Air Leak
IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study
Study to collect post-market safety data for HUD IBV Valve System, a device to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged air leaks following lobectomy, segmentectomy, or…
- Trial name
- HUD-PAS (NCT01166516)
- Testing
- Treatment with HUD IBV Valve System
- Where
- 13 sites in United States
- Volunteers
- 32 people
- Sponsor
- Olympus Corporation of the Americas
Monitoring of Regional Distribution of Ventilation, Monitoring of Lung Volume
Prospective, Open, Non-interventional Study to Assess the Ability of an Electrical Impedance Tomograph (PlumoVista 500)
This observational PMCF study will be conducted to generate and gather clinical data from the intended target population of pediatric patients.
- Trial name
- PV500ped (NCT04873999)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Drägerwerk AG & Co. KGaA
Pulmonary Emphysema
Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema
This study will evaluate the effects of baseline collateral ventilation status on outcomes following treatment with AeriSeal System in patients with advanced upper-lobe predominant heterogenous emphysema.
- Trial name
- CV+/- (NCT01520740)
- Testing
- Emphysematous Lung Sealant
- Where
- 13 sites in Germany, Israel
- Volunteers
- 100 people
- Sponsor
- Aeris Therapeutics
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
AeriSeal System for Lung Volume Reduction
The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Emphysema, Lung Diseases
- Trial name
- NCT01051258
- Testing
- AeriSeal System
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Aeris Therapeutics
Emphysema, Chronic Obstructive Pulmonary Disease
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
To establish and confirm the safety and clinical utility of BTVA applied unilaterally for lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.
- Trial name
- BTVA (NCT01102712)
- Testing
- BTVA System
- Where
- 10 sites in Australia, Austria and 2 more
- Volunteers
- 34 people
- Sponsor
- Uptake Medical Corp
Pulmonary Arterial Hypertension
Assessmet of Patients With PAH Right Ventricular Volume
The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with…
- Trial name
- NCT01557582
- Testing
- Ventripoint Medical System
- Where
- 7 sites in United States, Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VentriPoint Diagnostics Ltd.
Emphysema
Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema
The PneumRx Lung Volume Reduction Coil (LVRC) has been shown to effectively improve quality of life, exercise capacity, and static lung volumes, in patients with emphysema.
- Trial name
- NCT01421082
- Testing
- Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Advanced Upper Lobe Predominant Emphysema
Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00716053
- Testing
- BLVR
- Volunteers
- 225 people
- Sponsor
- Aeris Therapeutics
Emphysema, Pulmonary Disease, Chronic Obstructive
A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema
The Pulmair Implantable Artificial Bronchus (IAB) is a device intended for implantation into the diseased bronchi of emphysema patients.
- Trial name
- IAB-1 (NCT05087641)
- Testing
- IAB System
- Where
- 3 sites in Brazil, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Pulmair Medical, Inc.
COPD, Chronic Hypercapnic Respiratory Failure
Intelligent Volume Assured Pressure Support to Improve Sleep Quality and Respiratory Events in Patients With Non Invasive Ventilation
Aim of this prospective randomized trial is to compare non invasive ventilation (NIV) with pressure control (BiPAP-ST) to volume assured pressure support (iVAPS) with regards to sleep quality and alveolar ventilation in patients…
- Trial name
- NCT01986413
- Testing
- pressure controlled ventilation BIPAP ST, volume assured pressure support IVAPS, NIV
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, COPD
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD…
- Trial name
- CLAIM (NCT02442206)
- Testing
- QVA149
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Emphysema
A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)
Use of the Chartis® Assessment System prior to EBV Treatment
- Trial name
- NCT01101958
- Testing
- Chartis System, Endobronchial Valve (EBV) Treatment
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pulmonx Corporation
Pulmonary Emphysema
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00435253
- Testing
- BLVR Treatment
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aeris Therapeutics
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Emphysema, Chronic Obstructive Pulmonary Disease
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous upper lobe emphysema.
- Trial name
- BTVA (NCT01041586)
- Testing
- BTVA System
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Uptake Medical Corp
Emphysema
Evaluation of the PneumRx Lung Volume Reduction Coil to Treat Emphysema
The objective of this study is to demonstrate the safety of the PneumRx Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc.
- Trial name
- NCT01220908
- Testing
- Lung Volume Reduction Coil (LVRC), Coils
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Emphysema
Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to determine the effective dose of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205920
- Testing
- BLVR Hydrogel
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Aeris Therapeutics